Table 3.

Relative risk of new onset diabetic complications by patient characteristics

Characteristics	Composite complications RR (95% CI)
Age	1.006 (1.005–1.007)a
Men (Ref. women)	0.93 (0.92–0.95)a
CCI	1.018 (1.013–1.023)a
Baseline DCSI	1.26 (1.25–1.27)a
Insulin	1.07 (1.03–1.11)a
Aspirin	1.07 (1.06–1.09)a
Clopidogrel	0.96 (0.94–0.98)a
Sarpogrelate	1.00 (0.97–1.02)
Cilostazol	0.99 (0.95–1.03)
ACEI/ARB	0.99 (0.98–1.01)
Statin	0.92 (0.91–0.93)a
Number of antidiabetics
1	Reference
2	1.01 (1.00–1.03)
3 +	1.13 (1.10–1.17)a
Antidiabetics therapy
Mono therapy
Metformin	Reference
DPP4-I	0.77 (0.70–0.85)a
Sulfonylurea	1.29 (1.27–1.32)a
Glucosidase	1.25 (1.18–1.33)a
Dual therapy
Metformin + Sulfonylurea	Reference
Metformin + DPP4-I	0.71 (0.69–0.73)a

Abbreviation: CCI Charlson comorbidity index score, ACEI/ARB angiotensin-1 converting enzyme Inhibitor/angiotensin-2 receptor blocker, DPP4-I dipeptidyl peptidase-4 inhibitor

^a statistically significant